您当前所在的位置:首页 > 产品中心 > 产品详细信息
191732-72-6 分子结构
点击图片或这里关闭

3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione

ChemBase编号:363
分子式:C13H13N3O3
平均质量:259.26062
单一同位素质量:259.09569129
SMILES和InChIs

SMILES:
O=C1N(C2CCC(=O)NC2=O)Cc2c1cccc2N
Canonical SMILES:
O=C1CCC(C(=O)N1)N1Cc2c(C1=O)cccc2N
InChI:
InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)
InChIKey:
GOTYRUGSSMKFNF-UHFFFAOYSA-N

引用这个纪录

CBID:363 http://www.chembase.cn/molecule-363.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
IUPAC传统名
lenalidomide
3-(4-amino-1-oxo-2,3-dihydro-1H-isoindol-2-yl)piperidine-2,6-dione
商标名
Revimid
Revlimid (Celgene)
Revlimid
别名
CDC 501
CC-5013
IMiD3
lenalidomide
Lenalidomide
Revlimid
3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidinedione
1-Oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
(3S)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione
Revimid
Lenalidomide
3-(4-AMino-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CAS号
191732-72-6
MDL号
MFCD18064659
MFCD22207056
PubChem SID
160963826
46505725
PubChem CID
216326

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 11.611916  质子受体
质子供体 LogD (pH = 5.5) -0.70813346 
LogD (pH = 7.4) -0.70788205  Log P -0.7078522 
摩尔折射率 68.2981 cm3 极化性 25.243994 Å3
极化表面积 92.5 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P -0.43  LOG S -2.05 
溶解度 2.33e+00 g/l 

分子性质

分子性质

理化性质 安全信息 药理学性质 产品相关信息 生物活性(PubChem)
溶解度
DMSO expand 查看数据来源
Soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL. expand 查看数据来源
外观
Tan Solid expand 查看数据来源
熔点
260-263°C (dec.) expand 查看数据来源
疏水性(logP)
-0.4 expand 查看数据来源
保存条件
-20°C expand 查看数据来源
-20°C Freezer expand 查看数据来源
保存注意事项
IRRITANT expand 查看数据来源
MSDS下载
下载链接 expand 查看数据来源
下载链接 expand 查看数据来源
TSCA收录
false expand 查看数据来源
作用靶点
TNF-alpha expand 查看数据来源
生物活性机理
Inhibits the expression of cyclooxygenase-2 (COX-2) expand 查看数据来源
Interfering with the immune system and angiogenesis expand 查看数据来源
纯度
95+% expand 查看数据来源
98% expand 查看数据来源
成盐信息
Free Base expand 查看数据来源
质检报告
下载链接 expand 查看数据来源
应用领域
Used against multiple myeloma and myelodysplastic syndromes expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank Selleck Chemicals Selleck Chemicals TRC TRC
DrugBank -  DB00480 external link
Item Information
Drug Groups approved; investigational
Description Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia]
Indication For the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Pharmacology Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions.
Toxicity The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.
Affected Organisms
Humans and other mammals
Biotransformation The metabolic profile of lenalidomide in humans has not been studied. In healthy volunteers, approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion. The process exceeds the glomerular filtration rate and therefore is partially or entirely active.
Absorption Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear.
Half Life 3 hours
Protein Binding 30%
Elimination In healthy volunteers, approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion.
References
List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. [Pubmed]
Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. [Pubmed]
Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. [Pubmed]
External Links
Wikipedia
Drugs.com
Selleck Chemicals -  S1029 external link
Research Area
Description Cancer,Myelofibrosis, Mantle cell lymphoma
Biological Activity
Description Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM.
Targets TNF-α
IC50 13 nM [1]
In Vitro Lenalidomide strongly induces IL-2 and sIL-2R production. Lenalidomide-induced tyrosine phosphorylation of CD28 on T cells is followed by a down-stream activation of NF-κB. [2] Lenalidomide and pomalidomide inhibits autoubiquitination of CRBN in HEK293 T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA). Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplifies pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression. Long-term selection for Lenalidomide resistance in H929 myeloma cell lines is accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and Lenalidomide, CRBN protein is undetectable. [3] Lenalidomide prevents induction of defects by down-regulating tumor cell inhibitory molecule expression. Lenalidomide prevents induction of tumor-induced T cell lytic synapse dysfunction. Lenalidomide treatment blocks CLL cell-induced T cell actin synapse dysfunction, mimicks antibody blockade, and down-regulates expression of CLL inhibitory ligands and their receptors on T cells. Lenalidomide treatment prevents tumor-induced immune suppression in FL, DLBCL, HL, MM, SCC, and OC and down-regulates immunosuppressive ligand expression on all tumor cells examined. CTL killing function significantly increases following antibody blockade of CLL inhibitory ligands or Lenalidomide treatment compared to control treatments. Treatment of autologous CLL-T cell co-cultures with Lenalidomide reverses impaired CD8+ T cell lytic synapse formation and granzyme B trafficking. [4]
In Vivo The induction of angiogenesis by bFGF is significantly inhibited by oral treatment of Lenalidomide in a dose-dependent manner. Lenalidomide significantly decreases the percentage of vascularized area from 5.16% (control group) to 2.58% (50 mg/kg). Lenalidomide significantly reduces the calculated total MVL from 21.07 (control) to 8.11 (50 mg/kg). Lenalidomide significantly inhibites HUVEC migration through the fibronectin-coated membranes towards 0.1 ng/mL of bFGF at 100 μM, 1 ng/mL of VEGF at concentrations of 10 μM and 100 μM. [5]
Clinical Trials Lenalidomide has entered in a Phase II clinical trial in the treatment of chronic lymphocytic leukemia.
Features
Combination Therapy
Description Lenalidomide plus Dexamethasone displays very synergistic results with combination index less than 0.1. [6] At 0.01 μM (in DU145 cells) and 1 μM (in PC3 cells) Lenalidomide reduces the mean IC50 for Docetaxel by 42% and 36% respectively. In PC3 cells, 1 μM Lenalidomide significantly enhances the apoptotic activity of Docetaxel. [7] Lenalidomide reveals synergistic effect in vitro with Bortezomib in co-culture system associating the MCL cell line Jeko-1 to the dendritic-like cells BDCM, by modifying the secretion pattern of these latest. [8] Treated with a combination of Lenalidomide and Docetaxel after the tumors has reached 160?mm2, the tumor growth rate is significantly reduced, and animal survival (as determined by the length of time taken for tumors to reach 15?cm3) is increased from 48 days to 59 days. [9]
Protocol
Kinase Assay [1]
Assay for inhibition of TNF synthesis by human PBMCs Human PBMCs from normal donors are obtained by Ficoll?Hypaque density centrifugation. Cells (106 cells/mL) are cultured in RPMI supplemented with 10 AB+ serum, 2 mM l-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin. Lenalidomide is dissolved in DMSO at 20 mg/mL; further dilution is done with culture medium. The final DMSO concentration in all assays including the controls is 0.25%. Lenalidomide is added to cells 1 hour prior to the addition of LPS. PBMCs (106 cells/mL) are stimulated with 1 μg/mL of LPS from Salmonella minnesota R595. Cells, in triplicate, are incubated with LPS for 18?20 hours at 37 °C in 5% CO2. Supernatants are then harvested and assayed for cytokine levels. In some experiments, supernatants are kept frozen at ?70 °C until use. Cell viability is assayed by Trypan blue exclusion dye method. The concentration of TNFα in the culture supernatants is determined by ELISA. Lenalidomide is assayed in a minimum of three separate experiments. Percent inhibition is determined as 100 × [1 ? (cytokine(experimental)/cytokine(control))].
Animal Study [5]
Animal Models Adult male Sprague-Dawley rats bearing HUVECs cells
Formulation 0.5% DMSO
Doses 50 mg/kg and 250 mg/kg
Administration Administered via i.p.
References
[1] Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.
[2] Zangari M, et al. Expert Opin Investig Drugs. 2005, 14(11), 1411-1418.
[3] Lopez-Girona A, et al. Leukemia. 2012.
[4] Ramsay AG, et al. Blood, 2012, 120(7), 1412-1421.
[5] Dredge K, et al. Microvasc Res. 2005, 69(1-2), 56-63.
[6] Henry JY, et al. Prostate. 2012, 72(8), 856-867.
[7] Ocio EM, et al. Haematologica, 2010, 95(5), 794-803.
[8] Henry JY, et al. J Clin Oncol, 2010, 28(suppl), Abst e13155.
[9] Moros A, et al. Canc Res, 2012, 72(8, Suppl 1), Abstr #1942.
Toronto Research Chemicals -  L328000 external link
Lenalidomide is an immunomodulatory drug; analog of Thalidomide.

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle